Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Multicenter Study
. 2024 Nov;19(6):925-939.
doi: 10.1007/s11523-024-01094-5. Epub 2024 Sep 20.

Impact of First-Line Osimertinib and Other EGFR-Tyrosine Kinase Inhibitors on Overall Survival in Untreated Advanced EGFR-Mutated Non-small Cell Lung Cancer in Japan: Updated Data from TREAD Project 01

Makoto Hibino  1 , Yoshinori Imamura  2 , Rai Shimoyama  3 , Tomoya Fukui  4 , Ryuta Fukai  5 , Akihiko Iwase  6 , Yukihiro Tamura  7 , Yusuke Chihara  8 , Takafumi Okabe  9 , Kiyoaki Uryu  10 , Tadahisa Okuda  11   12 , Masataka Taguri  11 , Hironobu Minami  2   13
Affiliations
Multicenter Study

Impact of First-Line Osimertinib and Other EGFR-Tyrosine Kinase Inhibitors on Overall Survival in Untreated Advanced EGFR-Mutated Non-small Cell Lung Cancer in Japan: Updated Data from TREAD Project 01

Makoto Hibino et al. Target Oncol. 2024 Nov.

Abstract

Background: Osimertinib shows higher effectiveness than first-generation epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors (TKIs) in the initial treatment of EGFR-mutated non-small cell lung cancer. However, its superiority in terms of overall survival in the Asian population, especially Japanese patients, remains uncertain.

Objective: To evaluate the survival benefit of osimertinib over other EGFR-TKIs in Japanese patients, using real-world data. METHODS : As part of the Tokushukai REAl-world Data project, a retrospective multi-institutional study across 46 hospitals in Japan was conducted to evaluate the overall survival of patients with advanced EGFR-mutated non-small cell lung cancer using propensity score matching. The study involved patients receiving osimertinib as the first-line treatment (1L-Osi), those initially treated with other EGFR-TKIs (1L-non-Osi), and those receiving osimertinib after initial EGFR-TKI treatment (2L/later-Osi) between April 2010 and December 2022 and followed up until April 2023.

Results: Among 1062 Japanese patients with EGFR-mutated non-small cell lung cancer, 416 (39.2%) received 1L-Osi, while 646 (60.8%) received 1L-non-Osi, including 139 (13.1%) who received 2L/later-Osi. Within these groups, 416 (39.2%), 293 (27.6%), and 75 (7.1%) patients received first-line EGFR-TKI treatment post-osimertinib approval as a later-line treatment in Japan (March 2016). After propensity score matching, the overall survival of the 1L-Osi group was comparable to that of the 1L-non-Osi group in the post-March 2016 subset (n = 283, 42.0 vs 42.4 months). Similar trends were observed in the Del19 and L858R subgroups. The median overall survival of the 2L/later-Osi group was notably long: 60.2 months post-March 2016 (n = 75). A subgroup analysis based on initial EGFR-TKI treatment in the 1L-non-Osi and 2L/later-Osi groups revealed no significant differences among the gefitinib, erlotinib, and afatinib groups.

Conclusions: Based on real-world data, osimertinib did not show a significant improvement in overall survival compared to other EGFR-TKIs as a first-line treatment for EGFR-mutated advanced non-small cell lung cancer in the Japanese (Asian) population.

Clinical trial registration: This study was registered at the University Hospital Medical Information Network Clinical Trials Registry on 9 March, 2023 (identification UMIN000050552).

PubMed Disclaimer

Conflict of interest statement

Declarations Funding No external funding was used in the preparation of this article. Conflict of interest Makoto Hibino received research funding from and engaged in collaborative research with Shionogi & Co., Ltd. outside the submitted work. Tomoya Fukui received speakers’ bureau fees/honoraria from AstraZeneca, Boehringer Ingelheim, Chugai Pharm, Eli Lilly, Nippon Kayaku, Novartis Pharma, Ono Pharm, Pfizer, and Taiho Pharm outside the submitted work. Imamura received speakers’ bureau fees/honoraria from Bayer, Bristol-Myers Squibb, Daiichi-Sankyo, Pfizer, and Ono Pharm outside the submitted work. Minami received speakers’ bureau fees/honoraria from Daiichi-Sankyo and Ono Pharm; research funding from Astelas-Amgen Biopharma, Bayer, Bristol-Myers Squibb, Chugai, Daiichi-Sankyo, Incite, Novartis, Ono Pharm, Pfizer, and Rakuten Medical; and scholarship donations from Bayer, Chugai, Daiichi-Sankyo, Eisai, Kyowa-Kirin, Lilly, Ono Pharmaceutical, Pfizer, Taiho Pharma, and Takeda outside the submitted work. These organizations had no role in the study design; in the collection, analysis, and interpretation of data; in the writing of the report; and in the decision to submit the article for publication. Rai Shimoyama, Ryuta Fukai, Akihiko Iwase, Yukihiro Tamura, Yusuke Chihara, Takafumi Okabe, Uryu Kiyoaki, Tadahisa Okuda, and Masataka Taguri have no conflicts of interest that are directly relevant to the content of this article. Ethics approval The study was conducted following the principles of the Declaration of Helsinki and was reviewed and approved by the Ethics Committee of the Tokushukai Group on 2 March, 2023 (approval number: TGE 01427-008). This study was registered at the University Hospital Medical Information Network Clinical Trials Registry on 9 March, 2023 (identification UMIN000050552). Consent to participate The requirement for obtaining informed consent from patients was waived because this was a retrospective analysis of anonymized patient data. Patients were allowed to opt out of the research use of their data, and related information is publicly available on the Tokushukai Medical Group website. Consent for publication Not applicable. Availability of data and material The data supporting the findings of this study are available from the corresponding author on reasonable request. Code availability Not applicable. Authors’ contributions Conceptualization, data curation, formal analysis, investigation, methodology, resources, writing (original draft): MH. Resources, writing (review and editing): KU. Resources, writing (review and editing): RS. Resources, writing (review and editing): TF. Resources, writing (review and editing): RF. Resources, writing (review and editing): AI. Resources, writing (review and editing): YT. Resources, writing (review and editing): YC. Resources, writing (review and editing): MF. Formal analysis: TO. Formal analysis: MT. Writing (review and editing): YI. Writing (review and editing): HM.

Figures

Fig. 1
Fig. 1
Patient flowchart. EGFR epidermal growth factor receptor, TKI tyrosine kinase inhibitor, VEGF vascular endothelial growth factor
Fig. 2
Fig. 2
Kaplan–Meier curves for overall survival (OS) in the first-line treatment with osimertinib (1L-Osi) and first-line treatment with non-osimertinib epidermal growth factor receptor-tyrosine kinase inhibitors (1L-non-Osi) groups: a throughout the study period, b after March 2016, c throughout the study period using propensity score matching, and d after March 2016 using propensity score matching. CI confidence interval, HR hazard ratio, NA not available
Fig. 3
Fig. 3
Kaplan–Meier curves for overall survival (OS) in the second-line/later-osimertinib (following first-line treatment with non-osimertinib epidermal growth factor receptor-tyrosine kinase inhibitors) group. The black line represents data from the entire study period, whereas the red line represents data from patients who received first-line treatment after March 2016. CI confidence interval
Fig. 4
Fig. 4
Kaplan–Meier curves for overall survival by epidermal growth factor receptor mutation type. a First-line treatment with osimertinib (1L-Osi) and first-line treatment with non-osimertinib epidermal growth factor receptor-tyrosine kinase inhibitor (1L-non-Osi) groups during the entire study period, b 1L-Osi and 1L-non-Osi groups after March 2016, c 2L/later-Osi (osimertinib in second-line or later-line treatment following first-line treatment with non-osimertinib epidermal growth factor receptor-tyrosine kinase inhibitors) group during the entire study period, and d 2L/later-Osi group after March 2016
Fig. 5
Fig. 5
Kaplan–Meier curves for overall survival (OS) based on the epidermal growth factor receptor-tyrosine kinase inhibitors used in first-line therapy among patients treated with non-osimertinib epidermal growth factor receptor-tyrosine kinase inhibitors as their initial treatment (treatment initiated after March 2016). CI confidence interval, NA not available
Fig. 6
Fig. 6
Kaplan–Meier curves for overall survival (OS) based on the epidermal growth factor receptor-tyrosine kinase inhibitors used in first-line therapy among patients treated with osimertinib as second-line or later-line treatment following first-line treatment with non-osimertinib epidermal growth factor receptor-tyrosine kinase inhibitors. CI confidence interval, NA not available
See this image and copyright information in PMC

References

    1. Shi Y, Au JS-K, Thongprasert S, Srinivasan S, Tsai C-M, Khoa MT, et al. A prospective, molecular epidemiology study of EGFR mutations in Asian patients with advanced non-small-cell lung cancer of adenocarcinoma histology (PIONEER). J Thorac Oncol. 2014;9:154–62. 10.1097/JTO.0000000000000033. - PMC - PubMed
    1. Riely GJ, Wood DE, Ettinger DS, Aisner DL, Akerley W, Bauman JR, et al. Non-small cell lung cancer, Version 4.2024, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2024;22:249–74. 10.6004/jnccn.2204.0023. - PubMed
    1. Akamatsu H, Ninomiya K, Kenmotsu H, Morise M, Daga H, Goto Y, et al. The Japanese Lung Cancer Society Guideline for non-small cell lung cancer, stage IV. Int J Clin Oncol. 2019;24:731–70. 10.1007/s10147-019-01431-z. - PMC - PubMed
    1. Soria J-C, Ohe Y, Vansteenkiste J, Reungwetwattana T, Chewaskulyong B, Lee KH, FLAURA Investigators, et al. Osimertinib in untreated EGFR-mutated advanced non-small-cell lung cancer. N Engl J Med. 2018;378:113–25. 10.1056/NEJMoa1713137. - PubMed
    1. Uryu K, Imamura Y, Shimoyama R, Mase T, Fujimura Y, Hayashi M, et al. Stepwise prolongation of overall survival from first to third generation EGFR-TKIs for EGFR mutation-positive non-small-cell lung cancer: the Tokushukai REAl-world Data project (TREAD 01). Jpn J Clin Oncol. 2024;54:319–28. 10.1093/jjco/hyad162. - PubMed

Publication types

MeSH terms